Clinical Trial Update: Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity

View source ↗

Summary

A completed clinical trial evaluating modifiable biomarkers to predict immunotherapy response and toxicity in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer
• Stage Iva Non-small Cell Lung Cancer
• Stage Ivb Non-small Cell Lung Cancer

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Status: COMPLETED